Quantum BioPharma Ltd.
QNTM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.08 | 0.03 | 0.02 |
| FCF Yield | -164.36% | -29.73% | -93.97% | -59.61% |
| EV / EBITDA | 0.07 | -2.16 | -0.64 | -0.03 |
| Quality | ||||
| ROIC | -143.24% | -179.56% | -88.32% | -61.70% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.46 | 0.59 | 1.06 | 0.61 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 36.49% | 62.27% | -35.07% | -11.06% |
| Safety | ||||
| Net Debt / EBITDA | 0.36 | 0.15 | 0.74 | 1.16 |
| Interest Coverage | -339.16 | -79,563.54 | -561.83 | -486.19 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |